NEW YORK, March 24 (GenomeWeb News) - BioTrove and Blue Sky will collaborate to create a screening portfolio for challenging drug targets, Biotrove said this week.
Under the agreement, BioTrove will use Blue Sky proteins as a component of an assay used by BioTrove's RapidFire platform to screen for biomarkers.
The collaboration will focus initially on targets in metabolic disorders and oncology, BioTrove said.
Financial details were not provided.